Investment Thesis
Kyntra Bio exhibits severe financial distress with negative stockholders equity of -$43.8M, indicating balance sheet insolvency. The company generates minimal revenue ($3.7M) against massive operating losses (-$13.8M), while carrying $75M in long-term debt it cannot service from operations (interest coverage: -5.7x). With negative free cash flow of -$13.9M annually and current cash reserves of $37M, the company has approximately 2.7 years of runway before insolvency unless it achieves transformative clinical or commercial milestones.
Strengths
- Strong short-term liquidity position with current ratio of 3.61x and quick ratio of 3.48x
- Net income loss improved 485.6% year-over-year, suggesting operational efficiency gains despite losses
- Maintains $37M in cash reserves providing near-term operational flexibility
Risks
- Balance sheet insolvency with negative stockholders equity of -$43.8M; equity value theoretically zero or negative
- High debt burden ($75M) cannot be serviced from operations; interest coverage is -5.7x indicating inability to pay interest from earnings
- Significant cash burn of -$13.9M annually with minimal revenue of $3.7M; company consumes cash for every dollar of revenue generated
- Negligible revenue growth (0.0% YoY) indicates lack of commercial momentum or market traction
Key Metrics to Watch
- Cash balance depletion rate and months of runway remaining
- Operating cash flow trend and path to positive FCF
- Revenue growth acceleration and gross margin development
- Debt restructuring events, covenant violations, or refinancing activities
- Clinical trial progression or regulatory milestones indicating value creation potential
Financial Metrics
Revenue
3.7M
Net Income
-15.2M
EPS (Diluted)
$-3.76
Free Cash Flow
-13.9M
Total Assets
109.6M
Cash
37.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-369.7%
Net Margin
-406.6%
ROE
N/A
ROA
-13.9%
FCF Margin
-371.5%
Balance Sheet & Liquidity
Current Ratio
3.61x
Quick Ratio
3.48x
Debt/Equity
N/A
Debt/Assets
108.5%
Interest Coverage
-5.69x
Long-term Debt
75.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T08:45:27.379848 |
Data as of: 2026-03-31 |
Powered by Claude AI